Table 2 In vivo experimental data of radiosensitization effects
From: CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
Authors | CDK4/6 inhibitor | Xenograft | Efficacy with radiotherapy |
|---|---|---|---|
Hashizume et al. [42] | Palbociclib | Intracranial ATRT (BT12) (BT16) Glioblastoma (GBM43) | Median survival time increased by 24 to 26 days (1.4-fold) Median survival time increased by 31.5 to 34.5 days (3.3-fold) Median survival time increased by 10 to 13.5 days (1.6-fold) |
Whittaker et al. [43] | Palbociclib | Glioblastoma (RN1) | Median survival time increased by 8 days |
Naz et al. [44] | Abemaciclib | NSCLC (H460) | Tumor regrowth delay 8 and 9 days, inhibit IR-induced tumor vasculogenesis |
Tao et al. [30] | Palbociclib and Trametinib | NSCLC (A549) | Tumor volume ↓ Proliferation ↓ Apoptosis ↑ |
Huang et al. [45] | Palbociclib | HCC (Huh7) | Tumor volume ↓ Tumor weight ↓ |
Li et al. [50] | Ribociclib and CA3 | EAC (Flo-1 XTR) | Tumor volume ↓ Tumor weight ↓ |
Barton et al. [52] | Palbociclib | Ink4a-ARF- deficient BSG a mouse model | Median survival time increased by 10 days (19%) |